Compare Illumina, Inc. (ILMN) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Illumina, Inc. trades at $189.99 (market cap $27.94B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $58.77. The key difference: Illumina, Inc. is trading nearer its 52-week high, Vanguard Emerging Markets Stock Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | VWO | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | — |
52-Week High | $194.33 | $61.24 |
52-Week Low | $91.00 | $49.54 |
Enterprise Value | $29.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
VWO trades at $57.93, up 0.16% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF's low expense ratio of 0.06% and 2.4% dividend yield (The Motley Fool, 2026-06-29) appeal to cost-conscious investors. Recent news highlights strong capital inflows into emerging markets and comparisons with peers like EEM, emphasizing VWO's cost advantage and exposure to developing economies without heavy China reliance.
Outlook: VWO offers diversified emerging market access at low cost, but faces risks from geopolitical tensions and China's economic volatility. Investor sentiment is mixed, with technicals suggesting caution despite fundamental strengths in expense efficiency and yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
